Advertisement
U.S. markets open in 2 hours 21 minutes
  • S&P Futures

    5,203.25
    -11.50 (-0.22%)
     
  • Dow Futures

    39,160.00
    -63.00 (-0.16%)
     
  • Nasdaq Futures

    18,182.50
    -49.00 (-0.27%)
     
  • Russell 2000 Futures

    2,045.00
    -4.80 (-0.23%)
     
  • Crude Oil

    82.55
    -0.17 (-0.21%)
     
  • Gold

    2,157.50
    -6.80 (-0.31%)
     
  • Silver

    25.14
    -0.13 (-0.51%)
     
  • EUR/USD

    1.0850
    -0.0027 (-0.25%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.62
    +0.29 (+2.02%)
     
  • dólar/libra

    1.2684
    -0.0044 (-0.35%)
     
  • USD/JPY

    150.5150
    +1.4170 (+0.95%)
     
  • Bitcoin USD

    63,000.07
    -5,006.44 (-7.36%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.05
    -16.50 (-0.21%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Merck and Endocyte's ovarian cancer drug fails in trial

May 2 (Reuters) - Merck & Co Inc and Endocyte Inc said they had stopped a late-stage trial of their experimental ovarian cancer drug because it did not improve survival rates without the cancer worsening.

The trial was testing the drug, vintafolide, in combination with a chemotherapy drug, pegylated liposomal doxorubicin (PLD), compared to PLD plus a placebo.

An independent safety committee reviewing the trial had recommended that it be halted, the companies said in separate statements.

(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)

Advertisement